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Abstract
Background and Objective: Psychosocial costs, or quality of life costs, account for
psychological distress, pain, suffering and other negative experiences associated with
cancer. They contribute to the overall economic burden of cancer that patients expe-
rience. But this category of costs remains poorly understood. This hinders opportuni-
ties to make the best cancer control policy decisions. This study explored the
psychosocial cost burden associated with cancer, how studies measure psychosocial
costs and the impact of this burden.
Methods: A systematic literature review of academic and grey literature published
from 2008 to 2018 was conducted by searching electronic databases, guided by the
Institute of Medicine’s conceptualization of psychosocial burden. Results were ana-
lyzed using a narrative synthesis and a weighted proportion of populations affected
was calculated. Study quality was assessed using the Ottawa-Newcastle instrument.
Results: A total of 25 studies were included. There was variation in how psychosocial
costs were conceptualized and an inconsistent approach to measurement. Most stud-
ies measured social dimensions and focused on the financial consequences of paying
for care. Fewer studies assessed costs associated with the other domains of this bur-
den, including psychological, physical, and spiritual dimensions. Fourty-four percent
of cancer populations studied were impacted by psychosocial costs and this varied
by disease site (38%-71%). Two studies monetized the psychosocial cost burden,
estimating a lifetime cost per case ranging from CAD$427753 to CAD$528769.
Studies were of varying quality; 60% of cross-sectional studies had a high risk of bias.
Conclusions: Consistency in approach to measurement would help to elevate this
issue for researchers and decision makers. At two-thirds of the total economic bur-
den of cancer, economic evaluations should account for psychosocial costs to better
inform decision-making. More support is needed to address the psychosocial cost
burden faced by patients and their families.
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1 | INTRODUCTION
The rising costs of cancer treatment and supportive care1 are a concern
for health care systems, patients, and their families. Due to the large
economic burden of cancer care, it is important to have an accurate
estimate of the costs associated with cancer and a good understanding
of who bears those costs.2 Cost-of-illness studies can help translate the
adverse effects of diseases into dollars, which is one input to support
decision-making. This information is crucial to help set future health
budgets, to help aid in the allocation of scarce resources and, ultimately,
supports decision-making for cancer control systems.
Generally, the economic burden of cancer care has been
described as three broad categories: direct costs, indirect costs, and
psychosocial costs3 (Figure 1). Direct costs are those that include the
use of resources for medical and non-medical care as well the time
spent obtaining such care. Indirect costs are those that result from the
loss of resources and opportunities due to cancer. Psychosocial costs
have generally been defined as intangible costs associated with can-
cer, such as pain and suffering.4 Psychosocial costs are entirely borne
by patients and their families and are the least well understood cate-
gory of the three.
The psychosocial burden of cancer refers to the myriad ways that
cancer and the cancer experience impact patients and their families,
including caregivers. This burden is conceptualized as resulting from
impacts on four domains: physical, psychological, spiritual, and social
well-being (Figure 2). A recent study found most cancer survivors in
Canada face ongoing and unmet needs related to psychological (90%),
physical (80%), and practical (50%) challenges.5 These challenges and
their collective burden can affect the quality of life of patients and
family members involved in their care.5 For this reason, psychosocial
costs or the psychosocial cost burden have been described as synony-
mous with quality of life costs.3,6
Psychosocial costs represent the additional cost to individuals’
well-being that is associated with cancer. A seminal definition
describes psychosocial costs as follows:
Illness and disease are responsible for a wide variety of
deteriorations in quality of life that are frequently
referred to as psychosocial costs… Disease may bring
about personal catastrophes that are not reflected in
the direct and indirect economic costs that are usually
estimated for a specific disease… These include, but
are not limited to, undesired changes in life plans, anxi-
ety, reduced self-esteem and feeling of well-being, and
other emotional problems… psychosocial costs are a
significant, and very likely quite large, component of
the total burden of illness. To ignore them, or misrep-
resent them, can result in an underestimate of the
impact of disease and bias the decision-making
process.7
In other literature, psychosocial costs have been described as an
intangible cost due to the challenges of assigning a monetary value.8
These costs are distinct from, and in addition to, the direct costs that
may be paid for using additional health care services to address psy-
chosocial issues, for example, to see a psychologist. Psychosocial
costs are also related to, but distinct, from the indirect costs borne
by society due to lost productivity that may result from an unre-
solved symptom burden during treatment that prevents a patient
from working.
These challenges with the definition of psychosocial costs have
resulted in a mixed approach to measurement. Some studies approach
measurement of these costs using generic assessments of quality
of life that may not capture the full realm of psychosocial burden
F IGURE 1 Contributors to the
economic burden of cancer (from 3)
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according to the four key domains, namely: physical, psychological,
spiritual, and social well-being. While some of this impact may in
fact be captured in generic quality of life assessments, it is unclear
whether and to what extend the generic tools are able to capture
the full breadth and impact of the psychosocial burden of illness.
There is also a varied approach to measurement of psychosocial
costs. The inconsistent approach to examining these costs in the
literature creates missed opportunities for leveraging these learn-
ings to inform decision-making and resource allocation. Further-
more, despite recognition of the additional burden caused by
psychosocial costs raised in the Hosdgeson and Meiners 1982
paper, the methods to advance to measurement and use of psy-
chosocial cost data have been scare, particular in the health eco-
nomics literature.
Understanding the scope and scale of the cancer burden borne
by patients and families is important to properly and accurately
measure the overall economic burden of cancer to society. It is
also required if we are to take seriously our commitments and
value placed on patient-centered care within the cancer control
system. Moreover, this information is necessary to inform decision-
making around best models of care to support patients and the
patient experience throughout the cancer trajectory. It is also criti-
cal for monitoring the potential impact—even inadvertent—of shifts
in cost out of the system that may result in an economic burden
for patients.
The objective to this review was to answer the following research
questions: (a) what is the psychosocial cost burden associated with
cancer and how do studies measure psychosocial costs? and (b) what
is the prevalence and impact of this burden?
2 | METHODS
2.1 | Search strategy, selection criteria, and
retrieval of articles
The review was registered on PROSPERO CRD42019133975.
In this review, we drew on the definition of psychosocial burden
from the Institute of Medicine’s conceptual framework. We aimed to
understand and describe the estimated costs associated with this bur-
den, either in monetary terms or when defined as intangible costs.
Psychosocial consequences of cancer can constitute a cost to patients
and caregivers that may or may not have been monetized. These con-
sequences also have potential to lead to direct economic impacts for
patients and their families, which also may or may not be monetized.
This review intentionally casts its scope broadly to capture all these
potential conceptualizations of psychosocial costs, aligned with the
definition of psychosocial costs provided by Hodgson 1982.7
A detailed search strategy was developed and informed by the
Institute of Medicine’s conceptual framework for the psychosocial
burden of cancer,9 with input from a medical librarian and content
experts (see online supplement in Data S1). This framework was used
as it reflects the general consensus on the main features of the psy-
chosocial burden associated with cancer and we were interested in
understanding all of the associated costs. After piloting and adjusting
the search strategy, we searched the following databases: Pubmed,
Medline, Embase, CINAHL, PsycInfo, Econlit, and the Johanna Briggs
EBP database. Google Scholar was searched using keywords from the
main search strategy. In addition, grey literature was searched using a
modified search strategy in OpenGrey and Grey Literature Report.
F IGURE 2 Dimensions of the psychosocial burden of cancer (adapted from 9)
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The reference lists of all included papers were reviewed to identify
potentially relevant papers. We also consulted experts to identify
other relevant studies. Only studies in English were considered.
We aimed to include all evidence on the psychosocial cost burden
associated with cancer in all populations. We included pediatric and
adult cancers to understand whether there were important differ-
ences in the cost estimates, the approaches to measurement used
across studies as well as the extent to which this issue was measured
across different patient populations. For pediatric cancers, the care-
giver’s/parent’s costs, reflect a main source of economic burden asso-
ciated with these types of cancers. In addition, and importantly,
patient and caregiver costs are ultimately borne and shared at the
household-level. For these reasons, both adult and pediatric
populations were considered within scope of this review.
The titles and abstracts of all retrieved papers were indepen-
dently screened for eligibility by two individuals and, subsequently,
the full text articles of the remaining articles, using pre-specified inclu-
sion criteria. Articles were included if they were published between
the years 2008 and 2018, were a primary research study that focused
on measuring or describing the psychosocial cost burden associated
with cancer, and were conducted in a population of patients at any
point along the cancer care continuum (from diagnosis to palliative
and end-of-life care, including survivorship). Articles were excluded if
they were not written in English. Consistency in the screening process
between individuals was ensured by having each person indepen-
dently review between 20 and 50 papers and then compare their
results with each other, discussing and resolving any discrepancies
and consulting with the research team as needed.
A form was developed to guide the data extraction process. The
form captured information on study characteristics (eg, jurisdiction,
setting, design, data sources, or tools used) measurement/definition
of outcomes, key demographic characteristics of the research popula-
tion (eg, age, proportion female, cancer site, point of care along the
cancer care continuum, perspective), dimensions of the psychosocial
burden (physical, spiritual, social, and psychological) and its measure-
ment, and key findings.
We assessed the risk of bias in the cross-sectional and cohort
studies using the Ottawa-Newcastle quality appraisal tool.10 The tool
assessed study quality using a “star system,” from three broad per-
spectives: the selection of the study population; the comparability of
the study population; and the ascertainment of either the exposure or
outcome of interest.
The results were first analyzed using a narrative synthesis that
focused on distilling the main dimensions of the psychosocial cost
burden that were the focus of the studies, how they were measured,
the factors that contributed to the psychosocial cost burden, and
notable differences in this burden between cancer populations. Stud-
ies were categorized according to how they conceptualized the psy-
chosocial costs burden, including costs associated with physical,
spiritual, social, and psychological well-being (Figure 2). Subsequently,
all estimates of the proportion of the study population who experi-
enced a psychosocial cost burden, regardless of how measured, were
synthesized and a weighted average of the proportion and 95%
confidence intervals were calculated for each cancer type, by study
population (adult and pediatric) and for all studies. The purpose of the
weighted average was to describe how prevalent the psychosocial
cost burden was across the published studies. Given the heterogene-
ity in how the costs were estimated, cost data were not synthesized.
This systematic review is reported in accordance with the Pre-
ferred Reporting Items for Systematic Reviews and Meta-analyses
(PRISMA) guidelines (online appendix). This was a systematic review,
so ethics approval was not required.
3 | RESULTS
3.1 | Summary of included studies
There were 883 studies retrieved in the search of the academic data-
bases; an additional 11 papers were identified from references lists. No
relevant studies were found in the search of the grey literature. After
screening and full text review, 25 papers met the inclusion criteria and
were included for analysis6,11-34 (Figure 3). A summary of the included
studies is shown in Table 1. The studies reflected a total of 11 331 indi-
viduals. Most studies were conducted in adult populations (88%) and
recruited from clinical settings (64%) in the United States (84%); two
studies were conducted in Canada and two in Ireland. Most studies
investigated the psychosocial cost burden associated with multiple can-
cers, covering the following disease sites: colon/rectum (17.1%), lung
(11.4%), breast (11.4%), prostate (8.6%), head, and neck (5.7%); one
study each was conducted in populations with cancer of the esophagus,
brain, kidney, pancreas, testes, uterus, and bladder. There was also one
study each conducted in populations with sarcomas and multiple mye-
loma. Most of the study populations were undergoing treatment (64%)
or were cancer survivors (27%) (Figure 4).
The Ottawa-Newcastle tool was used to assess the risk of bias in
cross-sectional studies (20/26 studies) (Figure S1-online supplement in
Data S1). There was a high risk of selection bias in 95% of the studies
due to the recruitment of convenience or non-representative samples.
There was also a high risk of bias related to the measurement of out-
comes in 76% of studies, as most studies did not conduct a blinded mea-
surement of outcomes or use a gold standard or validated tool. However,
most studies completed appropriate analyses that adjusted for potential
confounding variables, resulting in 75% of studies being assessed as hav-
ing a low risk of bias in the comparability of results. Taken together, the
overall quality of the evidence in this review was assessed as being low.
However, as the focus of this study was on understanding the state of
the literature on this topic, the evidence is still deemed to provide useful
insights to address the main research questions.
3.2 | What is the psychosocial cost burden
associated with cancer and how is it measured?
There were 24 of 25 studies that focused on the social dimension of
the psychosocial burden of cancer. The focus of these studies was on
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measuring the prevalence of negative financial consequences or
impacts associated with the private (ie, out-of-pocket) costs of cancer.
There was inconsistency in the terminology, definitions, and measure-
ment of outcomes related to financial consequences associated with
cancer. Most studies measured the negative consequences to patients
and families in terms of the financial burden (n = 10), financial strain or
stress (n = 4), or financial toxicity (n = 3) reported by patients and their
families. There was also wide variation in the tools used to measure
these outcomes, with no gold standard tool acknowledged and few
validated tools used to measure the outcomes (Table 2). The cost to
patients due to social support needs or poor social functioning was
also investigated in a minority of studies.
The burden on patients associated with psychological and physi-
cal consequences of cancer and their impact on patients’ well-being
was investigated in six studies and were described in terms of quality
of life costs. In these studies, quality of life costs were explicitly con-
ceptualized as the cost to patients of lost opportunities for social
engagement reduced social functioning and the impact on their
F IGURE 3 PRISMA Flow Chart of
Included Studies
F IGURE 4 Summary of studies according to cancer care continuum
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TABLE 1 Summary of studies included in the review (n = 25)
Studies
Cancer site; cancer continuum
stage
Design;
Setting; n
Psychosocial dimension Proportion of study
population affected %
(95%CI) Cost estimate? Key findingsPhysical Spiritual Social Psychological
Bestvina
et al 2014,
USA
Breast, esophageal, kidney,
lung, CRC pancreas,
prostate, sarcoma, testicular,
uterine (69%: breast, lung,
CRC, prostate);
Treatment
Cross-
sectional;
Clinical setting;
300
✓ 16 (12,21) No Financial distress increases the
odds of non-adherence to
treatment.
Bona et al
2014,
USA
All cancers (pediatric);
Treatment
Cross-
sectional;
Clinical setting;
71
✓ 27 (15,31) No The distribution of the
financial burden associated
with cancer is inequitable,
poorer families reporting
disproportionate income
losses and impact.
Bona et al.
2016,
USA
All cancers (pediatric);
Treatment
Cross-
sectional;
Clinical setting;
99
✓ 29 (18,40) No Low-income and household
material hardship (HMH) are
prevalent in a significant
proportion of newly
diagnosed pediatric
oncology families despite
psychosocial supports
available. HMH is a
quantifiable and remediable
measure of poverty.
Cagle et al.
2016,
USA
All cancers;
End of life
Cross-
sectional;
Community;
176
✓ 51 (41,62) No The cost of care was a major
financial burden for most
patients and a third
indicated using all or most of
their savings. Households
with younger or minority (ie,
other race) cancer patients
are especially at-risk for
financial burden. Financial
stress and strain were linked
to multiple elements of the
cancer care experience, they
are related concepts
(r = 0.46, P < .01), but are
not synonymous.
Chongpison
et al
2016,
USA
Rectal;
Survivorship
Cross-
sectional;
Insured
community;
✓ ✓ ✓ 22 (18,26) No Depression was associated
with greater perception of
financial burden. Screening
for depression and assessing
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TABLE 1 (Continued)
Studies
Cancer site; cancer continuum
stage
Design;
Setting; n
Psychosocial dimension Proportion of study
population affected %
(95%CI) Cost estimate? Key findingsPhysical Spiritual Social Psychological
576 financial well-being might
improve care among long-
term survivors
Creswell
et al 2014,
USA
All cancers (pediatric);
Treatment, survivorship
Case–control;
Clinical setting
and
community;
215
✓ ✓ 35 (21,48) No Financial difficulties have a
strong independent
association with depressive
symptoms among the
parents of pediatric patients.
de Souza
et al 2016,
USA
All cancers;
Treatment, end-of-life
Cross-
sectional;
Clinical
setting;
233
✓ ✓ nr No The COST measure
demonstrated reliability and
validity in measuring
financial toxicity. Its
correlation with HRQOL
indicates that financial
toxicity is a clinically
relevant patient-centered
outcome.
Fletcher
et al.
2010,
USA
All cancers (pediatric);
Treatment
Qualitative;
Clinical setting;
9
✓ nr No Four main costs to parents
resulting from children’s
cancer: financial and work
issues; health of the mothers
and other family members;
and upheaval of family life.
Huntington
et al.
2015,
USA
Multiple Myeloma;
Treatment
Cross-
sectional;
Clinical setting;
100
✓ 71 (54,87) No Financial toxicity and use of
coping mechanisms were
common in insured cancer
populations.
Jung et al
2018,
Canada
Bladder;
All stages
Economic
evaluation;
Model;
199
✓ ✓ ✓ Nr Yes—$428 689
per case
At $50 000 per quality
adjusted life year, quality of
life costs account for 65% of
the total lifetime cost of
cancer.
This accounts for the impact
on health of impaired social
role engagement, pain,
suffering, and loss of
employment
Kale et al
2016,
USA
All cancers (33%: breast, CRC,
prostate);
Survivorship
Cross-
sectional;
Community;
1380
✓ ✓ ✓ 31 (28,34) No Cancer-related financial
burden was associated with
lower health-related quality
of life, increased risk of
(Continues)
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TABLE 1 (Continued)
Studies
Cancer site; cancer continuum
stage
Design;
Setting; n
Psychosocial dimension Proportion of study
population affected %
(95%CI) Cost estimate? Key findingsPhysical Spiritual Social Psychological
depressed mood, and a
higher frequency of
worrying about cancer
recurrence among survivors
Landwehr
et al 2016,
USA
All cancers;
Survivorship
Cross-
sectional;
Grantee
database;
371
✓ nr No Financial hardship is associated
with medical non-adherence,
which affects outcomes. It
impacts younger adults more
than older adults.
Litzelman
et al.
2011,
USA
Pediatric (brain);
Treatment and survivorship
Cross-
sectional;
Clinical setting;
75
✓ ✓ 71 (52,90) No The caregiver burden and
financial stress mediate the
effect of caring for a child
with cancer and impact
parental mental health-
related QOL
Massa et al
2018,
USA
Head and neck;
Treatment and survivorship
Cross-
sectional;
Clinical setting;
100
✓ 64 (48,80)—financial
stress, tests
18 (10,26)—stress, lost
income
24 (14,34)—stress
27 (17,37)—stress,
transport
31 (21,42)—stress, tests
No Patients with limited social
support, high financial stress,
functional deficits, and those
with transportation burdens
have greater demands for
care.
Meisenberg
et al
2015,
USA
All cancer
(42%: breast, CRC, lung);
Treatment
Cross-
sectional;
Clinical setting;
132
✓ 47 (35,59) No Financial stress was measured
as a side effect of the OOP
cost burden associated with
cancer
Meneses
et al.
2012,
USA
Breast;
Survivorship
Prospective
cohort;
Clinical trial;
132
✓ 71 (54,87) No >50% of survivors reported at
least one economic burden
event related to either work
or financial hardship. More
than a quarter reported
changes in income or
sacrificing family plans.
Among those who worked,
>15% reported changes in
motivation, productivity or
quantity (missed days) of
work. These events, in turn,
were negatively associated
with financial burden
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TABLE 1 (Continued)
Studies
Cancer site; cancer continuum
stage
Design;
Setting; n
Psychosocial dimension Proportion of study
population affected %
(95%CI) Cost estimate? Key findingsPhysical Spiritual Social Psychological
O’Brien et al
2016,
Ireland
Head and neck,
Survivorship
Cross-
sectional;
Clinical setting;
583
✓ ✓ 47 (41,53) No Psychological unmet needs
comprise seven out of the
10 top needs in this sample
Regenbogen
et al.
2014,
USA
Colorectal;
Post-operative
Cross-sectional
Clinical setting;
937
✓ 71 (66,76) No Significantly greater personal
financial burden among
patients who with
postoperative complications,
addition, longer time off
work and more likely to
never resume working.
Coping strategies included
cutting back on spending for
food, clothes, and recreation
and to accumulate debt or
not pay bills. High levels of
worry about finances.
Shankaran
et al.
USA
Colorectal;
Treatment
Cross-sectional
Registry;
284
✓ 38 (31,45) No Patients at greatest risk for
financial hardship and non-
adherence were younger;
had lower annual household
incomes; or were
unemployed, on work
disability, or on a leave-of-
absence.
Sharp et al
2012
Ireland
Breast, lung, prostate;
Treatment
Cross-sectional
Clinical setting;
654
✓ ✓ 32 (28,36) – Financial
strain
49 (44,54) – Financial
stress
No Depression risk was raised
three-fold in those reporting
cancer-related financial
stress (OR: 2.79)
Tompa et al.
2017,
Canada
Lung;
Treatment
Cost-of-illness;
Model;
2331
✓ ✓ nr Yes—
Mesothelioma:
C$528769/case
Lung cancer: C
$446288/case
At $50 000 per quality-
adjusted life year, 67.6% of
the total lifetime cancer cost
is attributed to quality-of life
costs.
This accounts for the intrinsic
value of health and value for
social role engagement.
Veenstra
et al.
2014,
USA
Colorectal;
Post-operative
Cross-sectional
Registry;
956
✓ 62 (57,67) No New tool developed and
validated to identify patients
at risk for financial burden
and inform policy
(Continues)
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TABLE 1 (Continued)
Studies
Cancer site; cancer continuum
stage
Design;
Setting; n
Psychosocial dimension Proportion of study
population affected %
(95%CI) Cost estimate? Key findingsPhysical Spiritual Social Psychological
interventions. There was
substantial financial burden
among most respondents,
with significantly higher
burden reported for those
on chemotherapy.
Zafar et al.
2015,
USA
Colorectal and lung;
Treatment and survivorship
Cross-sectional
Clinical setting;
1000
✓ 48 (44,53) No Financial burden is prevalent
among cancer survivors and
is associated with patients’
health-related quality of life,
even after adjusting for the
effects of income,
employment, disease status
and comorbidities
Zafar et al.
2013,
USA
All cancers
83%: breast, CRC, lung);
Treatment
Cross-sectional
Clinical setting;
254
✓ 42 (34,54) No Participants struggling to pay
for their cancer treatment
altered their lifestyles
considerably to defray out-
of-pocket expenses.
Copayment assistance
applicants were more likely
than non-applicants to
employ at least one lifestyle-
altering strategy to cope
with costs.
Zullig et al
2013,
USA
All cancers,
Treatment
Cross-sectional
Community;
164
✓ nr No In isolation, subjective financial
distress was associated with
medication non-adherence.
However, in multivariable
analysis, the role of financial
distress as a predictor of
non-adherence was less
clear
Note: CRC: colorectal cancer; nr: not reported; HRQOL, health-related quality of life. Cancer continuum stage includes the following: diagnosis, treatment, survivorship, and end-of-life care.
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intrinsic value of health.6,20 They were also measured as the cost to
individuals due to pain, suffering, and loss of enjoyment associated
with poor health due to cancer.20 Two instruments that were used to
quantify quality of life costs included the SF-1235 and the Health Utili-
ties Index (HUI)-3,36 both of which are validated instruments for mea-
suring health-related quality of life.
A minority of studies (n = 3) focused on the impact of psychologi-
cal distress and disorders such as stress, anxiety, and depression and
their relationship with negative financial outcomes. These studies con-
ceptualized the psychosocial cost burden in terms of the increased
risk of experiencing negative outcomes associated with declines in
one’s psychological well-being. Different tools were used in each
study, none of which was validated (Table 2).
There were no studies that measured the psychosocial cost bur-
den of cancer in a holistic way, accounting for all four of the dimen-
sions, and none of the studies explicitly measured the costs
associated with the spiritual dimension of this burden.
3.3 | What is the prevalence and impact of the
psychosocial cost burden?
The proportion of the study populations reporting psychosocial costs
associated with cancer varied between studies, from 16% of patients
reporting financial distress in a study of individuals with breast, esoph-
ageal, kidney, lung, pancreatic, prostate, sarcoma, testicular, or uterine
TABLE 2 Outcomes and tools used to measure the psychosocial cost burden of cancer
Psychosocial
domain Outcomes measured Tool
Validated
tool?
Physical
(n = 4)
Quality of life (n = 4) SF-12 Yes
City of Hope Quality of Life Colorectal Cancer No
Quality of life - breast cancer survivors No
Functional Assessment of Cancer Therapy: General
(FACT-G) questionnaire
Yes
Spiritual
(n = 0)
- -
Social
(n = 25)
Financial distress (n = 1) InCharge Financial Distress/Financial Well-Being
Scale
Yes
Family financial hardship (n = 1) Survey about Caring for Children with Cancer No
Household material hardship (n = 1) Author developed No
Financial strain and stress (n = 4) Author developed No
Depression Anxiety Stress Scales Yes
Life Events Questionnaire No
Financial burden (n = 10) Author developed No
Breast Cancer Finances Survey No
Financial toxicity
(n = 3)
COST survey Yes
Personal Financial Wellness Scale Yes
Financial Challenges
(n = 1)
Author developed No
Social support (n = 3) The Duke Social Support and Stress Scale Yes
Supportive Care Needs Survey No
Oslo-3 social support scale Yes
Social functioning (n = 1) HUI-3 Yes
Psychological
(n = 9)
Psychological distress or impairment (eg, anxiety,
depression) (n = 4)
SF-12 Yes
City of Hope Quality of Life Colorectal Cancer No
The Center for Epidemiologic Studies Depression
Scale
Yes
National Comprehensive Cancer Network Distress
Thermometer
Yes
Quality of life - breast cancer survivors No
Patient reported outcomes Yes
Depression Anxiety Stress Scales Yes
Stress (n = 1) Calgary Symptoms of Stress Inventory Yes
Note: Number of studies do not total 25 as some studies measured multiple dimensions of the psychosocial cost burden and used multiple tools.
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cancers11 to as high as 71% of patients reporting either a signifi-
cant financial burden or financial toxicity associated with treatment
for colorectal cancer28 and multiple myeloma.19 There was a lower
prevalence of this cost burden found in the studies of pediatric
populations, ranging from 27%12 to 35%16 of study populations
affected. As most studies were conducted in the United States,
where the majority of individuals are not covered under a publicly
funded health insurance system and often face significant out-of-
pocket costs associated with cancer, we looked at the prevalence
of the cost burden in non-US studies and found the estimates
ranged between 32%30 and 47%27 for the studies conducted in
Ireland. The prevalence of this cost burden was not estimated in
the two studies conducted in Canada.
Figure 5 shows the results of the weighted estimates of the prev-
alence of the psychosocial cost burden by cancer type. The highest
prevalence was found in study populations with multiple myeloma
(71%, 95% CI: 54%-87%), and the lowest estimate was found in stud-
ies that included multiple cancers types but predominately focused on
breast, colorectal, lung, and prostate cancers (38%, 95% CI: 30%-
47%). The weighted average for the prevalence of the psychosocial
cost burden across all studies was 44% (95% CI: 37%-51%). As most
studies focused on measuring the impact on social well-being and on
the financial impact of cancer, this estimate should be interpreted as
approximately 44% of cancer patients reported experiencing a finan-
cial or economic burden.
Several studies found this burden was associated with an
increased risk of facing negative outcomes including: treatment and
medication non-adherence,11,34 symptoms of depression,16,30 psycho-
logical distress,21 declines in quality of life33 and unmet physical, psy-
chological, sexual, and health system information needs.27
Two modeling studies estimated the cost of the psychosocial
burden associated with cancer as health-related quality of life costs,
measured using the SF-12 and the HUI.6,20 Both studies approached
this estimation by calculating the difference in QALYs between can-
cer and non-cancer populations and assigned monetary values for
the cancer-attributable QALYs between CAD$25000 and CAD
$100000, informed by the contingent-value literature.6 The lifetime
health-related quality of life cost per case of bladder cancer was esti-
mated as $428 689 (95% CI $427 753 to $438047), representing
65% of the total economic burden of this cancer.20 Similarly, the life-
time quality of life costs associated with each case of mesothelioma
and lung cancer were estimated at $528 769 and $446 288 respec-
tively, representing 67.6% of the total economic burden of these
cancers.6
4 | DISCUSSION
To the authors’ knowledge, this is the first systematic review to syn-
thesize studies on the psychosocial cost burden associated with can-
cer. The review suggests that approximately 44% of individuals
affected by cancer are impacted by psychosocial costs and that this
burden has far reaching implications, significantly increasing the likeli-
hood of poorer health, clinical, and economic outcomes for patients
and caregivers. The estimated lifetime costs of the psychosocial bur-
den were approximately CDN $428689 using conservative measures,
representing two-thirds of the total economic burden associated with
a cancer diagnosis. This review highlights that this burden is likely too
great to ignore, yet it remains a neglected topic in the published litera-
ture and potentially also in clinical settings.
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Most studies in this review focused narrowly on a selection of
constructs that related to the psychological and social domains of the
psychosocial burden of cancer and, in particular, the financial impact
of illness. This focus on financial impacts of cancer is likely a result of
most research originating from the US where the impoverishing con-
sequences of cancer are well documented.37 There was a lack of
emphasis in studies investigating and capturing sub-clinical levels of
distress that are nevertheless significant and important for under-
standing the experience of psychosocial burden from patient, family,
and caregiver perspectives. The findings of this review illustrate how
little is yet known about the full spectrum of the psychosocial costs
and their impact. However, that 44% of cancer patients were
impacted by mostly financial consequences of cancer is concerning
and aligns with findings from other studies.32,37,38
4.1 | Clinical practice and research implications
This review confirms that more research on this topic is needed,
particularly outside the United States. This review supports a call
to action for a research agenda to investigate psychosocial costs
more comprehensively in all settings given that we know that the
psychosocial burden of cancer transcends borders.9 Within this
agenda, there is also a need to better understand how this cost
burden changes (or not) across the cancer treatment trajectory and
into survivorship where the needs of cancer survivors change and
are less well understood and less well met.5 This will inform the
development of supports to better address the psychosocial burden
of survivors.
This review also confirms that there is an inconsistent approach
to the measurement of the psychosocial cost burden associated with
cancer. Most studies used customized or purpose-built measures,
resulting in a range of tools in use in practice. In part, this may be due
to the lack of a gold standard or validated approach for measurement.
This has limited opportunities for comparison within and between
cancer populations and across settings and this potentially hampers
efforts to elevate the importance of this issue. Furthermore, it is well
known that some sub-populations are more at risk of facing an eco-
nomic burden associated with cancer due to out-of-pocket,35,36,39
time,40-42 and indirect costs.43-45 A stronger commitment to consis-
tently measure psychosocial costs, including in diverse cancer
populations, is needed to determine who is most at risk and to help to
direct action to address any inequities that may be contributing to
such disparities in the economic burden of cancer.
The sole method used in the literature for monetizing the psycho-
social costs was to calculate the cost per quality adjusted life year.
Two generic tools, the SF-1246 and the HUI,47 were used to measure
health-related quality of life. However, both tools do not explicitly
capture elements relating to spiritual and social well-being and thus
they may not be sensitive enough to measure quality of life impacts
related to these domains. This issue—the extent to which existing
health-related quality of life metrics (eg, quality-adjusted life years)
capture the breadth of psychosocial costs—has important implications
for cancer care decision-making. First, these existing tools potentially
underestimate the psychosocial costs associated with cancer as they
do not account for all dimensions of the psychosocial burden. Second,
if these costs are to be included in economic evaluations of cancer
interventions to better reflect the potential costs and benefits associ-
ated with cancer care, it is important to gain a better understanding of
how to accurately capture and incorporate psychosocial costs to
ensure they are not inadvertently double-counted as both costs and
benefits (eg, quality of life). Finally, the tendency in economic evalua-
tions is to adopt a health care system perspective to best inform
health system decision-making.48 However, this review highlights the
importance of adopting a broader societal perspective in economic
evaluations to account for the significant psychosocial impact that is
associated with cancer and borne by patients and their families. A
recent systematic review of health interventions that included the
patient perspective found no studies included intangible or psychoso-
cial costs,49 further supporting that these costs are not routinely
incorporated. Economic evaluations that account for the psychosocial
burden associated with cancer should also be an input to support
informed decision-making, as this information will allow decision-
makers to weigh up the true value and cost-effectiveness of new can-
cer interventions.
4.2 | Study limitations
This study has limitations. We only included studies published in the
last 10 years to ensure that, to the extent possible, the costs and pol-
icy contexts reflected contemporary circumstances. We also limited
our inclusion criteria to English studies only. It is possible that we mis-
sed relevant studies; however, key experts were engaged to ensure
seminal papers were not missed. The study quality of most studies
was low. This limits the extent to which conclusions can be drawn but
emphasizes the need for a research agenda to improve the measure-
ment, breadth, and quality of studies on the psychosocial costs of can-
cer across settings.
5 | CONCLUSION
The prevalence of the psychosocial cost burden found in this review
supports a need for greater attention to address these costs, account
for them in the context of economic evaluations and improve the
psychosocial support programs available to cancer patients and
their families. Elevating the importance of psychosocial costs is
needed to drive efforts to develop more routine approaches to
measurement as well as efforts to use these data to support deci-
sion making to lessen the economic burden faced by cancer
patients and their families. Advancing our understanding of the
psychosocial costs of cancer will help to meet commitments to
patient-centred care and research by improving our understanding
of the full breadth of costs borne by patients and areas where
supportive care can best mitigate this burden.
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